Department of Radiation Oncology, Tumor Hospital of Harbin Medical University, Harbin, Heilongjiang, People's Republic of China.
Department of Breast Surgery, Tumor Hospital of Harbin Medical University, Harbin, Heilongjiang, People's Republic of China.
Med Oncol. 2024 Aug 22;41(9):233. doi: 10.1007/s12032-024-02477-4.
Breast cancer, as a highly prevalent cancer among women, is one of the main causes of female mortality due to cancer. There is a need for more treatment options to improve the survival time of breast cancer patients. Metastasis to distant organs is a standard indicator of advanced breast cancer and a primary cause of breast cancer mortality, making the control of breast cancer metastasis crucial. Targeted therapy, with its advantages of precision, high effectiveness, and minimal side effects, has garnered significant attention as a hot research topic in breast cancer treatment. Among these therapies, anti-angiogenic therapy aim to inhibit tumor angiogenesis, control tumor growth, and reduce metastasis. Additionally, anti-angiogenic therapy can restructure the tumor vasculature, enhancing the effectiveness of other anti-cancer drugs. Lenvatinib, an orally available small molecule multi-targeted tyrosine kinase inhibitor, exerts its anti-tumor effects mainly by inhibiting tumor angiogenesis and tumor cell proliferation. It has been approved for the treatment of thyroid cancer, renal cell carcinoma, and hepatocellular carcinoma. Due to its multi-targeted nature, lenvatinib not only has direct anti-tumor effects but also possesses immunomodulatory activity, which can enhance the tumor immune response. This makes it a promising candidate for a broad range of cancers. Recent studies have explored the role of lenvatinib in breast cancer, including its various mechanisms of action and its use as a monotherapy or in combination to control breast cancer progression. This review will summarize the molecular mechanisms and research progress of lenvatinib in breast cancer treatment, discussing its potential applications and therapeutic prospects in managing breast cancer.
乳腺癌是女性中高发的癌症之一，是女性癌症死亡的主要原因之一。因此，需要更多的治疗方案来改善乳腺癌患者的生存时间。远处器官转移是晚期乳腺癌的标准指标，也是乳腺癌死亡的主要原因，因此控制乳腺癌转移至关重要。靶向治疗以其精准、高效、副作用小等优点，成为乳腺癌治疗的热点研究课题。在这些治疗方法中，抗血管生成治疗旨在抑制肿瘤血管生成，控制肿瘤生长，减少转移。此外，抗血管生成治疗可以重构肿瘤血管，增强其他抗癌药物的疗效。仑伐替尼是一种口服小分子多靶点酪氨酸激酶抑制剂，主要通过抑制肿瘤血管生成和肿瘤细胞增殖发挥抗肿瘤作用。它已被批准用于治疗甲状腺癌、肾细胞癌和肝细胞癌。由于其多靶点特性，仑伐替尼不仅具有直接的抗肿瘤作用，还具有免疫调节活性，可增强肿瘤免疫反应。这使其成为多种癌症的有前途的候选药物。最近的研究探讨了仑伐替尼在乳腺癌中的作用，包括其各种作用机制以及作为单一疗法或联合疗法控制乳腺癌进展的应用。本文将总结仑伐替尼在乳腺癌治疗中的分子机制和研究进展，讨论其在乳腺癌治疗中的潜在应用和治疗前景。
